Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]
SEC Accession No. 0001683168-24-005796
Filing Date
2024-08-16
Accepted
2024-08-15 20:16:52
Documents
58
Period of Report
2023-09-30

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 2 FOR 9-30-23 coeptis_i10qa2-093023.htm   iXBRL 10-Q/A 1512401
2 CERTIFICATION coeptis_ex3101.htm EX-31.1 7549
3 CERTIFICATION coeptis_ex3102.htm EX-31.2 7541
4 CERTIFICATION coeptis_ex3201.htm EX-32.1 2473
5 CERTIFICATION coeptis_ex3202.htm EX-32.2 2470
  Complete submission text file 0001683168-24-005796.txt   8115384

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE coep-20230930.xsd EX-101.SCH 48387
7 XBRL CALCULATION FILE coep-20230930_cal.xml EX-101.CAL 49989
8 XBRL DEFINITION FILE coep-20230930_def.xml EX-101.DEF 211863
9 XBRL LABEL FILE coep-20230930_lab.xml EX-101.LAB 312455
10 XBRL PRESENTATION FILE coep-20230930_pre.xml EX-101.PRE 270723
61 EXTRACTED XBRL INSTANCE DOCUMENT coeptis_i10qa2-093023_htm.xml XML 1804850
Mailing Address 105 BRADFORD ROAD, SUITE 420 WEXFORD PA 15090
Business Address 105 BRADFORD ROAD, SUITE 420 WEXFORD PA 15090 724-934-6467
Coeptis Therapeutics Holdings, Inc. (Filer) CIK: 0001759186 (see all company filings)

EIN.: 981465952 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q/A | Act: 34 | File No.: 001-39669 | Film No.: 241213915
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)